ezbet slot
MAI Capital Management cut its stake in First Solar, Inc. ( NASDAQ:FSLR – Free Report ) by 8.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,724 shares of the solar cell manufacturer’s stock after selling 163 shares during the quarter. MAI Capital Management’s holdings in First Solar were worth $430,000 as of its most recent filing with the Securities and Exchange Commission. Other institutional investors and hedge funds have also recently bought and sold shares of the company. Electron Capital Partners LLC grew its stake in shares of First Solar by 81,947.0% in the 2nd quarter. Electron Capital Partners LLC now owns 7,669,757 shares of the solar cell manufacturer’s stock valued at $1,729,223,000 after buying an additional 7,660,409 shares in the last quarter. Robeco Institutional Asset Management B.V. grew its position in First Solar by 1,757.2% in the third quarter. Robeco Institutional Asset Management B.V. now owns 546,193 shares of the solar cell manufacturer’s stock worth $136,242,000 after acquiring an additional 516,783 shares in the last quarter. Anomaly Capital Management LP acquired a new position in shares of First Solar during the 2nd quarter worth $53,752,000. International Assets Investment Management LLC raised its holdings in shares of First Solar by 24,844.0% during the 3rd quarter. International Assets Investment Management LLC now owns 217,512 shares of the solar cell manufacturer’s stock valued at $542,560,000 after purchasing an additional 216,640 shares in the last quarter. Finally, Canada Pension Plan Investment Board lifted its stake in shares of First Solar by 2,429.1% in the 2nd quarter. Canada Pension Plan Investment Board now owns 174,530 shares of the solar cell manufacturer’s stock valued at $39,350,000 after purchasing an additional 167,629 shares during the last quarter. Hedge funds and other institutional investors own 92.08% of the company’s stock. First Solar Price Performance NASDAQ:FSLR opened at $186.05 on Friday. The company has a market capitalization of $19.92 billion, a price-to-earnings ratio of 16.02, a PEG ratio of 0.33 and a beta of 1.48. The company has a 50-day moving average of $212.65 and a 200-day moving average of $225.35. First Solar, Inc. has a 52 week low of $135.88 and a 52 week high of $306.77. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.44 and a current ratio of 2.14. Analyst Ratings Changes Several research firms have commented on FSLR. StockNews.com raised shares of First Solar from a “sell” rating to a “hold” rating in a research report on Tuesday, November 12th. Royal Bank of Canada cut their price objective on First Solar from $315.00 to $280.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 30th. Roth Mkm decreased their target price on First Solar from $320.00 to $280.00 and set a “buy” rating for the company in a research report on Tuesday, October 15th. BMO Capital Markets reiterated an “outperform” rating and set a $260.00 price target (down previously from $286.00) on shares of First Solar in a report on Wednesday, October 30th. Finally, UBS Group boosted their price objective on shares of First Solar from $350.00 to $360.00 and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Four analysts have rated the stock with a hold rating, twenty-three have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $279.04. Check Out Our Latest Research Report on FSLR First Solar Profile ( Free Report ) First Solar, Inc, a solar technology company, provides photovoltaic (PV) solar energy solutions in the United States, France, Japan, Chile, and internationally. The company manufactures and sells PV solar modules with a thin film semiconductor technology that provides a lower-carbon alternative to conventional crystalline silicon PV solar modules. Read More Want to see what other hedge funds are holding FSLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for First Solar, Inc. ( NASDAQ:FSLR – Free Report ). Receive News & Ratings for First Solar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for First Solar and related companies with MarketBeat.com's FREE daily email newsletter .THE Sun’s columnist Jane Moore last night told of her close friendship with Coleen Rooney — and how she dubbed the Wag “the Queen of Clean”. Jane was sent packing by the public in Friday’s first eviction from ITV1’s I’m A Celebrity. But she revealed how she and Coleen unexpectedly bonded over the 15 days they were together in the jungle. Our columnist also spoke of her medical drama after finding a blood-sucking leech attached to one of her boobs. In an exclusive interview in Oz, hours after she left the jungle, Jane, 62, said of Coleen , 38: “We ended up being quite close and having a lot of good chats. “She loves cleaning. She is the Queen of Clean. We were saying she needs her own TV show — Clean With Coleen . . . whatever play on words you can come up with. She’s a real grafter. "She really got on with the jobs in hand around the camp, without fanfare.” Jane said Coleen confided in her that she had wanted to become a journalist — and that she’d then urged Coleen to join her on ITV1’s Loose Women panel. She said: “I have suggested to her that she would make a very good Loose Woman. I said, ‘No pressure, but you could come on with me and GK (Barry) and Christine Lampard and I think you’d have a fantastic time, and I think you’d be very good.’ “I said, ‘So I’m just going to leave that with you.’ She just sort of nodded and smiled, so we’ll see.” Before Jane was axed, campmates spoke emotionally about their jungle experience and their fellow celebs. Coleen, wife of football legend Wayne Rooney, said Jane “scared” her when they met at the start of the series — because she is a journalist. But in a heartwarming moment, she added: “I feel like we’ve bonded more and more as time’s gone on.” Jane said she “totally gets” why Coleen was “nervous to be in the jungle for 15 days, 24/7 with a journalist”. She said she was “very mindful” of it — so much so that she opted not to choose Coleen as her partner for the race into camp on the launch show. But their friendship eventually began to develop in camp and they formed a connection. Ironically, despite trepidation towards journalists, Coleen told Jane she actually fancied it as a career at one point. Jane said: “I said to her, ‘What would you have done if you hadn’t ended up marrying Wayne?’ “And she said, ‘I think I would’ve liked to have been a journalist.’ “I said to her, ‘You would have made a very, very good journalist’ — because she has great observational skills. I liked her enormously, and I think, as she said at the very end, she bonded with me “She sits back, she watches everybody, and every so often she’ll chip in with something and it’s a really good point. “So I liked her enormously, and I think, as she said at the very end, she bonded with me. “There’s something that we had, weirdly, as probably the two people in camp that had the most to play for.” Asked if they will remain pals when the celebs go their separate ways, Jane added: “I hope so, but I think I’m going to leave that ball in her court.” Jane had been left angry last week after being put on washing up duty, the task she hates most. She jokingly accused boxer Barry McGuigan and McFly singer Danny Jones of being “sexist” for giving her the chore — despite her pleading for them not to. Jane had already spent nine days cleaning out the dunny and was annoyed with the new camp leaders. She also revealed she’d been battered with bruises she doesn’t know the cause of. But the culprit of one injury she sustained was clear — two marks on her breast after being latched on to by a leech in the night. She’d noticed her bra was blood-soaked after a freezing cold camp shower. Jane said: “It honestly looked like it had been shot in the chest. “I had two puncture marks and then it started to bruise. But I just went, ‘Oh, look, everyone, I’ve been breastfeeding a leech all night’. “And they all went, ‘How are you so calm?’ So I said, ‘Well, it’s dead now and it’s done, so there’s no point fretting about it. Anyway, it’s on the fire now. Little bugger.” After being evicted, she had an emotional reunion with daughters Grace, 20, and Ellie, 32, before heading off to enjoy her first hot shower in weeks. She then cracked a bottle of champagne and her blonde hair had its bounce back after a blow-dry from Danny’s mum, Kathy. She heaped praise on Danny — who she described as “absolutely delightful” - and the rest of her campmates. Barry, she said, is a “fighter from the top of his head to the tip of his toes”. And she insisted screaming Dean McCullough definitely acts “himself” and is an “absolute powerhouse of positivity”. Asked about a winner, she said she hopes radio DJ Melvin Odoom, 44, or Coleen can power on to victory. MELVIN SOMETIMES you don’t notice that Melvin is there because he’s not begging for your attention. He’s an absolute grafter. He is the loveliest guy, very respectful, kind and considerate. TULISA TULISA, the Female Boss. That is a title well-earned. Tulisa is a tough cookie. We’re alike in that we don’t let people in very easily. But when we do, you’re in for life. I’m hoping I’m in. RICHARD HE was in The Communards and he joined a monastery — you couldn’t get two more extreme things in life. He travels a lot, he loves being around people, but he also likes his own space. COLEEN I’VE got a new title for her — Col-Umbo. She’s quiet, quite reserved, but underestimate her at your peril. She’s the absolute hub of the Rooney household. She runs it like a machine. BARRY IF you are a friend of Barry’s you’re sorted because Barry will always be on your side. He’s a grafter. And he really struggled with being a leader because he wasn’t allowed to do anything. OTI SHE is a fabulous woman. The first week she was switched on the whole time. But week two was different. She wants more children and said: “If I don’t do it [the show] now, I probably won’t." DANNY I THINK he’s going to take a lot out of being in the jungle. He said: “I need to be in the moment more with my family and just in life.” He added: ‘I’m always working and fretting about work.’” G.K. BARRY SHE has absolutely no filter. She’s hilarious. But again, the first few days she was very GK Barry. Then there was this segue where she became Grace and had hilarious moments. ALAN HE is just so resourceful and practical. He’s a great guy and he’s a hard worker. He helped me a lot. When allowed he was there helping me lug the washing-up up and down steps. MAURA SHE’S hilarious and swears like a trooper. Maura is 100 per cent herself, which I really, really like. The guys doing the filming were laughing because she’s so funny. DEAN DEAN is an absolute powerhouse of positivity. He’s funny, he’s entertaining, he’s caring. But most of all, he is himself. In a quiet moment he said he got badly bullied at school. i'm A Celebrity is back for its 24th series, with a batch of famous faces living in the Aussie jungle. The Sun's Jake Penkethman takes a look at the stars on the show this year.. Coleen Rooney - Arguably the most famous name in the camp, the leading WAG, known for her marriage to Wayne Rooney , has made a grand return to TV as she looks to put the Wagatha Christie scandal behind her. The Sun revealed the mum-of-four had bagged an eye-watering deal worth over £1.5million to be on the show this year making her the highest-paid contestant ever. Tulisa - The popstar and former X Factor judge has made her triumphant TV comeback by signing up to this year's I'm A Celeb after shunning TV shows for many years. Known for being a member of the trio, N-Dubz, Tulisa became a household name back in 2011 when she signed on to replace Cheryl on ITV show The X Factor in a multi-million pound deal. Alan Halsall - The actor, known for playing the long-running role of Tyrone Dobbs on ITV soap opera Coronation Street, was originally signed up to head Down Under last year but an operation threw his scheduled appearance off-course. Now he has become the latest Corrie star to win over both the viewers and his fellow celebrities. Melvin Odoom - The Radio DJ has become a regular face on TV screens after rising to fame with presenting roles on Kiss FM, BBC Radio 1 and 4Music. Melvin has already been for a spin on the Strictly dancefloor and co-hosted The Xtra Factor with Rochelle Humes in 2015 but now he is facing up to his biggest challenge yet - the Aussie jungle . GK Barry - The UK's biggest social media personality, GK, whose real name is Grace Keeling, has transformed her TikTok stardom into a lucrative career. Aside from her popular social media channels, she hosts the weekly podcast, Saving Grace, and regularly appears on ITV talk show, Loose Women. She has even gone on to endorse popular brands such as PrettyLittleThing, KFC and Ann Summers. Dean McCullough - A rising star amongst this year's bunch of celebs , Dean first achieved notability through his radio appearances on Gaydio and BBC Radio 1. He was chosen to join the BBC station permanently in 2021 and has featured prominently ever since. He has enjoyed a crossover to ITV over the past year thanks to his guest slots on Big Brother spin-off show, Late & Live. Oti Mabuse - The pro dancer has signed up to her latest TV show after making her way through the biggest programmes on the box. She originally found fame on Strictly Come Dancing but has since branched out into the world of TV judging with appearances on former BBC show The Greatest Dancer as well as her current role on ITV's Dancing On Ice . Danny Jones - The McFly star was drafted into the programme last minute as a replacement for Tommy Fury. Danny is the second member of McFly to enter the jungle , after Dougie Poynter won the show in 2011. He is also considered a rising star on ITV as he's now one of the mentors on their Saturday night talent show, The Voice , along with bandmate Tom Fletcher. Jane Moore - The Loose Women star and The Sun columnist is braving the creepy crawlies this year. The star is ready for a new challenge - having recently split from her husband . It will be Jane's first foray into reality TV with the telly favourite having always said no to reality shows in the past. Barry McGuigan - Former pro boxer Barry is the latest fighting champ to head Down Under following in the footsteps of Tony Bellew and Amir Khan. It comes after a tough few years for Irish star Barry, who lost his daughter Danika to bowel cancer . He told The Late Late Show in 2021: "She was such an intrinsic part of the family that every day we ache." Maura Higgins - The Irish TV beauty first found fame on Love Island where she found a brief connection with dancer Curtis Pritchard . Since then, she has competed on Dancing On Ice as well as hosting the Irish version of the beauty contest, Glow Up. Since last year, she has been working on building up her career in the US by being the social media correspondent and host of Aftersun to accompany Love Island USA. She even guest hosted an episode of the spin-off, Love Island Games, in place of Maya Jama last year. Rev. Richard Coles - Former BBC radio host the Rev Richard Coles is a late arrival on I’m A Celebrity , and he's ready to spill the beans on his former employer. The former Communards and Strictly star , said the BBC did not know its a**e from its elbow last year. An insider said: "Rev Coles will have a variety of tales to tell from his wild days as a pop star in the Eighties, through to performing on Strictly and his later life as a man of the cloth."
NYC mayor Eric Adams staffer whose job is to 'promote diversity' RIPS Hamas hostage posters down and 'assaults eyewitness'
The 39-year-old takes charge for the first time in Sunday’s Premier League trip to promoted Ipswich having been confirmed as Erik ten Hag’s successor at the beginning of November. Amorim has made a positive impression since starting work at the United in an international fortnight that ended with an impressive first appearance in front of the media. The Portuguese was gregarious, engaging and smiley throughout Friday’s press conference but that warmth comes with a ruthlessness edge if players do not adhere to his approach. “You can be the same person,” head coach Amorim said. “Be a positive person that can understand this is one place to be, then there is the dressing room, there are some places to have fun, there are some places to work hard. “So, I can be ruthless when I have to be. If you think as a team, I will be the nicest guy you have ever seen. If there is someone just thinking about himself, I will be a different person. “I’m not that type of guy that wants to show that he is the boss. “They will feel it in the small details, that I can be the smiling one but then when we have a job to do I will be a different person, and they understand that.” ‘The Smiling One’ follows ‘the Special One’ as United’s second Portuguese manager, with Jose Mourinho one of five managers to try and fail to reach the heights scaled by Sir Alex Ferguson. The Scot retired as a Premier League champion in 2013 and the Red Devils have failed to launch a sustained title bid since adding that 20th top-flight crown. Asked about whether he will lean on Ferguson to understand the history of United and whether he has met him, Amorim said: “No, not yet. I didn’t have that opportunity. “It’s hard to copy someone, so I have to be me. Of course I’m not the best person in here to show the history of Manchester United. “It should be the club first and also me because I’m always paying attention on those details and try to focus our players in the history of the club, not the recent history. “You have to be very demanding. This is a club that needs to win, has to win, so we have to show that to our players but it’s a different time. “I cannot be the same guy that Sir Alex Ferguson was. It’s a different time. “I have to have a different approach, but I can also be demanding with a different approach, so that is my focus.” Like Ferguson in 1986, Amorim starts life at United in the November of a season that started with a paltry points tally. The 39-year-old acknowledges the timing makes “it’s so much harder” for him to imprint his style at a club whose youth foundations look in safe hands. “It’s the project of Manchester United,” Amorim said. “Nowadays, you need young guys, guys from the academy for everything. “To bring that history of the club because they feel the club in a different way. “And also because you have all these rules with financial fair play, when a player from our academy is so much different to the players that we bought and then we sell. “So, everything is connected. I will try to help all the players, especially the young ones.” Amorim’s first match will be a fascinating watch for onlookers, who have kept a particularly close eye on his work during his farewell to Sporting Lisbon. The Portuguese managed three final matches after being confirmed as United head coach, including a 4-1 Champions League win against Manchester City. Pep Guardiola’s side have dominated English football in recent years and the City boss this week signed a new deal until 2027. “I think it’s a problem for everybody here, but we have so much to do, we cannot focus on anyone,” Amorim said. “We just have to focus on our club, improve our club and not focus on the other clubs, so let’s focus on Manchester United. “It’s amazing (the test) – if you can beat that team it’s a good sign but, like I said, we are focused on Manchester United.”MPs who backed assisted dying Bill suggest concerns could see them change stanceWASHINGTON — President-elect Donald Trump called his meeting with Justin Trudeau productive and said the prime minister made a commitment to work with the United States to end the drug crisis amid the threat of stiff tariffs. "We discussed many important topics that will require both Countries to work together to address, like the Fentanyl and Drug Crisis that has decimated so many lives as a result of Illegal Immigration, Fair Trade Deals that do not jeopardize American Workers, and the massive Trade Deficit the U.S. has with Canada," Trump said in a post on Truth Social Saturday. Trudeau flew to Florida Friday evening to attend a dinner at Mar-a-Lago, where Trump's transition team is based. The in-person meeting came at the end of a rocky week in which Trump threatened to impose 25 per cent tariffs on all imports from Canada and Mexico, unless the two countries stop illegal border crossings and prevent illicit drugs from entering the United States. Trudeau thanked Trump for the dinner in a post on social media on Saturday. "I look forward to the work we can do together, again," Trudeau said in the post that included a picture of the two leaders sitting at a table and smiling together. Trump said he and Trudeau discussed the drug crisis and the president-elect made it "very clear that the United States will no longer sit idly by as our Citizens become victims" of the drug epidemic, which he attributed to cartels and fentanyl coming from China. "Prime Minister Trudeau has made a commitment to work with us to end this terrible devastation of U.S. Families," Trump posted. Trump's post did not directly mention tariffs and it's unclear whether the prime minister's visit has alleviated his concerns about the border. A statement from the Prime Minister's Office said the leaders "shared a productive wide-ranging discussion" centred on collaboration and strengthening the bilateral relationship. "As Canada's closest friend and ally, the United States is our key partner, and we are committed to working together in the interests of Canadians and Americans," the statement said. Trudeau had a notably rocky relationship with the Republican leader during the first Trump administration. However, the prime minister was the first G7 leader to visit Trump since the Nov. 5 election. Trudeau's invitation to Mar-a-Lago says a lot about the working relationship, a senior government source said, speaking on background. The dinner lasted more than three hours. Sources said Trudeau and Trump discussed trade, border security, Ukraine, NATO, icebreakers, the Middle East and the Group of Seven meeting in Alberta next year. They also talked about energy projects, including the Keystone Pipeline, Line 5, Trans Mountain Pipeline, and other topics related to liquefied natural gas. It was described as a friendly and welcoming dinner. Trump's social media post about the meeting with Trudeau appeared much more collaborative in tone than his response to a phone call with Mexican President Claudia Sheinbaum earlier this week after which he claimed a tariff victory. Trump wrote Wednesday that Sheinbaum had agreed to stop unauthorized migration across the border into the United States, "effectively closing our Southern Border." The Mexican president said that it was an "excellent" conversation but countered that her country was already doing its part. "We reiterate that Mexico's position is not to close borders but to build bridges between governments and between peoples," Sheinbaum said. Trump's return to the White House has brought concern to America's closest neighbours. He has long used the threat of import taxes to pressure other countries to do his bidding, saying last summer that "the most beautiful word in the dictionary is 'tariff.'" The Canada-U.S.-Mexico Agreement is up for review in 2026 and experts suspect this week's tariff announcement is a negotiating tactic. Canadian premiers have been calling on Trudeau to be more proactive in his approach to the incoming Trump administration. More than 77 per cent of Canadian exports go to the United States and provincial leaders have said Trump's duties would be devastating. Ontario Premier Doug Ford said he was glad Trudeau met Trump to learn more about the president-elect's concerns. But Ottawa has to show the premiers a plan to make the border more secure to avoid "disastrous tariffs," Ford said in a statement on social media. Alberta Premier Danielle Smith said she believed Trump and Trudeau had a constructive conversation. Speaking on her provincewide call-in radio shown Saturday, Smith said it was notable the conversation included the energy sector. Canada is the largest source of U.S. energy imports, and almost all Canadian crude oil exports went to its neighbour in 2023. The Alberta premier said it's critical to demonstrate how Canada's energy aligns with American's domestic and international interest. "Our strategy is this: let's talk to the Americans about the things we know they need and use that as a leverage point to make sure that we have zero tariffs on all goods," Smith said. — With files from Kyle Duggan in Ottawa, Rob Drinkwater in Edmonton and The Associated Press This report by The Canadian Press was first published Nov. 30, 2024. Kelly Geraldine Malone, The Canadian Press
Stock market today: Wall Street hits records despite tariff talk
Commanders place kicker Austin Seibert on injured reserveHurricane Helene may have spread invasive critters in Georgia
Green Ammonia Market to Grow by USD 3.21 Billion (2024-2028) Green Ammonia Introduction Boosts Growth, Report on AI-Driven Market Transformation - TechnavioPro-Palestine campaigners gather for Glasgow demonstration despite Storm Bert
Fall is the best time to think about cooking soup. Here’s 5 recipes you’ll want to trySwifties live-streaming Eras Tour concerts say they’re part of a ‘community’TCU_Battle 4 run (Lemmermann kick), 12:48. TCU_Williams 1 run (Lemmermann kick), 2:10. ARIZ_C.Hunter 17 pass from Fifita (Loop kick), :16. ARIZ_FG Loop 53, 8:08. ARIZ_FG Loop 43, 1:55. TCU_Williams 20 run (Lemmermann kick), :13. TCU_Battle 1 run (Lemmermann kick), 10:13. TCU_Richardson 38 pass from Hoover (Lemmermann kick), 7:51. ARIZ_C.Hunter 3 pass from Fifita (Patterson pass from Fifita), 14:53. TCU_Cook 6 run (Lemmermann kick), 10:23. TCU_J.Payne 30 run (Lemmermann kick), 5:25. ARIZ_Lane 70 fumble return (Loop kick), 1:00. RUSHING_Arizona, Conley 13-42, Reescano 3-11, (Team) 1-(minus 1), Fifita 5-(minus 14). TCU, Williams 9-80, Battle 6-28, Payne 3-27, Cook 6-20, D.Johnson 3-10, Seals 2-2, Sanders 2-0, (Team) 2-(minus 2), Hoover 5-(minus 18). PASSING_Arizona, Fifita 29-44-1-284, Tannenbaum 1-3-0-3. TCU, Hoover 19-26-1-252, Seals 2-3-0-51. RECEIVING_Arizona, McMillan 9-115, C.Hunter 8-47, Patterson 6-28, Conley 3-19, S.Olson 2-58, Hyatt 2-20. TCU, Richardson 6-107, McAlister 3-87, Bech 3-25, Williams 3-16, Rogers 2-43, Battle 2-13, P.Clark 1-15, Bruno 1-(minus 3). MISSED FIELD GOALS_None.KILLINGTON, Vt. (AP) — American skier Mikaela Shiffrin said she suffered an abrasion on her left hip and that something “stabbed” her when she crashed during her second run of a World Cup giant slalom race Saturday, doing a flip and sliding into the protective fencing. Shiffrin stayed down on the edge of the course for quite some time as the ski patrol attended to her. She was taken off the hill on a sled and waved to the cheering crowd before going to a clinic for evaluation. “Not really too much cause for concern at this point, I just can’t move,” she said later in a video posted on social media . “I have a pretty good abrasion and something stabbed me. ... I’m so sorry to scare everybody. It looks like all scans so far are clear.” She plans to skip the slalom race Sunday, writing on Instagram she will be “cheering from the sideline.” The 29-year-old was leading after the first run of the GS and charging for her 100th World Cup win. She was within sight of the finish line, five gates onto Killington’s steep finish pitch, when she an outside edge. She hit a gate and did a somersault before sliding into another gate. The fencing slowed her momentum as she came to an abrupt stop. Reigning Olympic GS champion Sara Hector of Sweden won in a combined time of 1 minute, 53.08 seconds. Zrinka Ljutic of Croatia was second and Swiss racer Camille Rast took third. The Americans saw Paula Moltzan and Nina O’Brien finish fifth and sixth. “It’s just so sad, of course, to see Mikaela crash like that and skiing so well,” Hector said on the broadcast after her win. “It breaks my heart and everybody else here.” The crash was a surprise for everyone. Shiffrin rarely DNFs — ski racing parlance for “did not finish.” In 274 World Cup starts, she DNF'd only 18 times. The last time she DNF'd in GS was January 2018. Shiffrin also has not suffered any devastating injuries. In her 14-year career, she has rehabbed only two on-hill injuries: a torn medial collateral ligament and bone bruising in her right knee in December 2015 and a sprained MCL and tibiofibular ligament in her left knee after a downhill crash in January 2024. Neither knee injury required surgery, and both times, Shiffrin was back to racing within two months. Saturday was shaping up to be a banner day for Shiffrin, who skied flawlessly in the first run and held a 0.32-second lead as she chased after her 100th World Cup win. Shiffrin, who grew up in both New Hampshire and Colorado and sharpened her skills at nearby Burke Mountain Academy, has long been a fan favorite. Shiffrin is driven not so much by wins but by arcing the perfect run. She has shattered so many records along the way. She passed Lindsey Vonn’s women’s mark of 82 World Cup victories on Jan. 24, 2023, during a giant slalom in Kronplatz, Italy. That March, Shiffrin broke Swedish great Ingemar Stenmark’s Alpine mark for most World Cup wins when she captured her 87th career race. To date, she has earned five overall World Cup titles, two Olympic gold medals — along with a silver — and seven world championships. In other FIS Alpine World Cup news, the Tremblant World Cup — two women’s giant slaloms at Quebec’s Mont-Tremblant scheduled for next weekend — were canceled. Killington got 21 inches of snow on Thanksgiving Day, but Tremblant — five hours north of Killington — had to cancel its races because of a lack of snow. ___ AP Sports Writer Pat Graham in Denver contributed to this report. ___ More AP skiing: https://apnews.com/hub/alpine-skiing Peggy Shinn, The Associated Press
According to DelveInsight's analysis, the market for Down syndrome is anticipated to increase during the forecast period (2024–2034), owing to the launch of emerging therapies such as AEF0217, ACI-24.060, LEUCETTINIB-21, BUNTANETAP, and others and healthcare spending globally. LAS VEGAS , Nov. 26, 2024 /PRNewswire/ -- DelveInsight's Down's Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Down's syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [ the United States , the EU4 ( Germany , France , Italy , and Spain ) and the United Kingdom , and Japan ]. Key Takeaways from the Down's Syndrome Market Report According to DelveInsight's analysis, the market size for Down's syndrome was found to be USD 241 million in the US in 2023. In 2023, the United States accounted for nearly 220K prevalent cases of Down's syndrome. The types of Down's syndrome include Trisomy 21, Robertsonian translocation, and Mosaicism. In 2023, among all types, Trisomy 21 accounted for the highest number of prevalent cases in the 7MM. Leading Down's syndrome companies such as AELIS FARMA, AC IMMUNE, PERHA PHARMACEUTICALS, ANNOVIS BIO, APHIOS THERAPEUTICS, and others are developing novel Down's syndrome drugs that can be available in the Down's syndrome market in the coming years. The promising Down's syndrome therapies in the pipeline include AEF0217, ACI-24.060, LEUCETTINIB-21, BUNTANETAP, APH-1104, and others. Discover which therapies are expected to grab the major Down's syndrome market share @ Down's Syndrome Market Report Down's Syndrome Overview Down's syndrome, also known as trisomy 21, is a genetic disorder caused by the presence of an extra copy of chromosome 21. This chromosomal anomaly disrupts normal development, resulting in a range of physical and cognitive differences. The condition is primarily caused by random genetic mutations during the formation of reproductive cells or early embryonic development, though advanced maternal age increases the likelihood of having a child with Down's syndrome. People with Down's syndrome typically exhibit distinct facial features, such as a flattened face, almond-shaped eyes that slant upward, and a small nose. Other common symptoms include developmental delays, intellectual disabilities, and a variety of health issues like heart defects, respiratory and hearing problems, and a higher susceptibility to infections. Despite these challenges, many individuals with Down's syndrome lead fulfilling lives with appropriate support. Diagnosis of Down's syndrome can occur prenatally through screening and diagnostic tests, such as blood tests and ultrasounds in the first and second trimesters, or through more definitive tests like chorionic villus sampling (CVS) and amniocentesis. Postnatal diagnosis is typically confirmed by a physical examination and a karyotype analysis to identify the extra chromosome. Early diagnosis and intervention can help address developmental needs and improve the quality of life for individuals with Down's syndrome. Down's Syndrome Epidemiology Segmentation The Down's syndrome epidemiology section provides insights into the historical and current Down's syndrome patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The Down's syndrome market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Diagnosed Prevalent Cases of Down's Syndrome Gender-specific Diagnosed Prevalent Cases of Down's Syndrome Type-specific Diagnosed Prevalent Cases of Down's Syndrome Age-specific Diagnosed Prevalent Cases of Down's Syndrome Diagnosed Cases of Down's Syndrome by Clinical Manifestations Down's Syndrome Treatment Market There is no single treatment for Down's syndrome; instead, care plans are customized to address each person's unique physical and intellectual needs, emphasizing their strengths and accommodating their limitations. For some individuals, immediate surgery may be needed after birth to correct heart defects or long-term dietary modifications may be required for digestive concerns. Common interventions include assistive devices such as hearing aids, mobility aids, and adaptive technology to support learning and daily tasks. People with Down's syndrome often face an earlier and more pronounced cognitive decline than the general population. Treatments for Down syndrome-associated dementia (DSAD) may include medications like rivastigmine, galantamine, memantine, and donepezil, which inhibit acetylcholine breakdown, providing notable benefits. Seizure management for those with Down syndrome may involve anticonvulsants like carbamazepine and phenytoin, although these can exacerbate other Down syndrome-related issues. Respiratory problems are also common due to immune deficiencies and respiratory tract abnormalities, often requiring antibiotics or inhaled bronchodilators for effective management. Along with pharmacological treatments, non-pharmacological therapies such as physical, speech, occupational, and behavioral therapies play a vital role in the early development of children with Down syndrome, promoting independence and productivity. Physical therapy aims to improve motor skills, build muscle strength, and enhance posture and balance, laying the groundwork for key abilities. Speech-language therapy focuses on boosting communication skills and addressing physical challenges like low muscle tone to avoid long-term complications. Occupational therapy adapts daily tasks to suit the individual's abilities, teaching crucial skills such as eating, dressing, writing, and using a computer. Emotional and behavioral therapies tackle challenges like frustration from communication barriers, compulsive behaviors, and ADHD by identifying triggers and creating strategies to foster positive behaviors and reduce undesirable ones. To know more about Down's syndrome treatment guidelines, visit @ Down's Syndrome Management Down's Syndrome Pipeline Therapies and Key Companies AEF0217: AELIS FARMA ACI-24.060: AC IMMUNE LEUCETTINIB-21: PERHA PHARMACEUTICALS BUNTANETAP: ANNOVIS BIO APH-1104: APHIOS THERAPEUTICS Discover more about Down's syndrome drugs in development @ Down's Syndrome Clinical Trials Down's Syndrome Market Dynamics The Down's syndrome market dynamics are expected to change in the coming years. The prevalence of Down syndrome has increased with the rise in lifespan over the past three decades. This, along with the combination of several neurological features in Down syndrome patients—such as language impairment, cognition, learning, and memory—has sparked intense neurodevelopmental research. Studies in this area hold promise for improving clinical care and quality of life for individuals with Down syndrome and their families, as well as for assessing ways to enhance communication between parents and children. A thorough understanding of the factors affecting pharmacotherapy in Down syndrome could significantly contribute to better clinical outcomes for these individuals. Furthermore, potential therapies are being investigated for the treatment of Down's syndrome, and it is safe to predict that the treatment space will significantly impact the Down's syndrome market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the Down's syndrome market in the 7MM. However, several factors may impede the growth of the Down's syndrome market. Down syndrome presents unique challenges in clinical treatment, as there is currently no medical cure or approved products available in the market, complicating the treatment process. This complexity is compounded by the lack of appropriate, validated scales to measure progress or side effects in participants with learning disabilities, making it difficult to gauge treatment impact effectively. Furthermore, recruiting participants and their families is challenging, adding to the difficulties in conducting research. Down syndrome is also associated with numerous health problems and high healthcare costs , and individuals may require more intensive monitoring for adverse effects, adherence, and treatment efficacy when managing medications. Conducting clinical studies on the efficacy of psychotropic medications in individuals with Down syndrome is particularly challenging due to the unique language and communication characteristics of this population. Moreover, Down's syndrome treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, Down's syndrome market growth may be offset by failures and discontinuation of emerging therapies , unaffordable pricing , market access and reimbursement issues , and a shortage of healthcare specialists . In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact Down's syndrome market growth. Down's Syndrome Market Report Metrics Details Study Period 2020–2034 Coverage 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. Down's Syndrome Market CAGR 3.81 % Down's Syndrome Market Size in the US in 2023 USD 241 Million Key Down's Syndrome Companies AELIS FARMA, AC IMMUNE, PERHA PHARMACEUTICALS, ANNOVIS BIO, APHIOS THERAPEUTICS, and others Key Pipeline Down's Syndrome Therapies AEF0217, ACI-24.060, LEUCETTINIB-21, BUNTANETAP, APH-1104, and others Scope of the Down's Syndrome Market Report Therapeutic Assessment: Down's Syndrome current marketed and emerging therapies Down's Syndrome Market Dynamics: Key Market Forecast Assumptions of Emerging Down's Syndrome Drugs and Market Outlook Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Down's Syndrome Market Access and Reimbursement Download the report to understand which factors are driving Down's syndrome market trends @ Down's Syndrome Market Trends Table of Contents 1 KEY INSIGHTS 2 REPORT INTRODUCTION 3 EXECUTIVE SUMMARY OF DOWN'S SYNDROME 4 DOWN'S SYNDROME MARKET OVERVIEW AT A GLANCE 4.1 MARKET SHARE BY THERAPIES (%) DISTRIBUTION OF DOWN'S SYNDROME IN 2020 IN THE 7MM 4.2 MARKET SHARE BY THERAPIES (%) DISTRIBUTION OF DOWN'S SYNDROME IN 2034 IN THE 7MM 5 KEY EVENTS 6 EPIDEMIOLOGY AND MARKET FORECAST METHODOLOGY 7 DOWN'S SYNDROME: DISEASE BACKGROUND AND OVERVIEW 7.1 INTRODUCTION 7.2 ETIOLOGY 7.3 TYPES OF DOWN'S SYNDROME 7.3.1 Trisomy 21 7.3.2 Translocation Down's syndrome 7.3.3 Mosaic Down's syndrome 7.4 CAUSES AND RISK FACTORS 7.5 COMPLICATIONS 7.6 OTHER HEALTH PROBLEMS 7.7 DIAGNOSIS 7.7.1 Screening Tests 7.7.2 Diagnostic Tests 7.8 TREATMENTS 7.8.1 Early Intervention and Educational Therapy 7.8.2 Treatment Therapies 7.8.3 Drugs and Supplements 7.8.4 Assistive Devices 8 CASE REPORTS 8.1 CASE STUDY: AN IPP TEAM HELPS 6-YEAR WITH DOWN'S SYNDROME IMPROVE COMMUNICATION SKILLS 9 EPIDEMIOLOGY AND PATIENT POPULATION 9.1 KEY FINDINGS 9.2 ASSUMPTIONS AND RATIONALE 9.3 TOTAL PREVALENT CASES OF DOWN'S SYNDROME IN THE 7MM 9.4 TYPE-SPECIFIC CASES OF DOWN'S SYNDROME IN THE 7MM 9.5 GENDER-SPECIFIC CASES OF DOWN'S SYNDROME IN THE 7MM 9.6 PREVALENT CASES OF DOWN'S SYNDROME BY CLINICAL MANIFESTATIONS IN THE 7MM 9.7 PREVALENT CASES OF DOWN'S SYNDROME BY AGE IN THE 7MM 9.8 THE UNITED STATES 9.8.1 Total Prevalent Cases of Down's Syndrome in the US 9.8.2 Type-specific Cases of Down's Syndrome in the US 9.8.3 Gender-specific Cases of Down's Syndrome in the US 9.8.4 Prevalent cases of Down's Syndrome by clinical manifestations in the US 9.8.5 Prevalent cases of Down's Syndrome by Age in the US 9.9 EU4 AND THE UK 9.9.1 Total Prevalent Cases of Down's syndrome in EU4 and the UK 9.9.2 Type-specific Cases of Down's syndrome in EU4 and the UK 9.9.3 Gender-specific Cases of Down's syndrome in EU4 and the UK 9.9.4 Prevalent cases of Down's syndrome by clinical manifestations in EU4 and the UK 9.9.5 Prevalent cases of Down's syndrome by Age in EU4 and the UK 9.10 JAPAN 9.10.1 Total Prevalent Cases of Down's syndrome in Japan 9.10.2 Type-specific Cases of Down's syndrome in Japan 9.10.3 Gender-specific Cases of Down's syndrome in Japan 9.10.4 Prevalent cases of Down's syndrome by clinical manifestations in Japan 9.10.5 Prevalent cases of Down's syndrome by Age in Japan 10 PATIENT JOURNEY 11 EMERGING DRUGS 11.1 KEY COMPETITORS 11.2 AEF0217: AELIS FARMA 11.2.1 Product Description 11.2.2 Other Developmental Activities 11.2.3 Clinical Development 11.2.3.1 Clinical Trials Information 11.2.4 Safety and Efficacy 11.3 ACI-24.060: AC IMMUNE 11.3.1 Product Description 11.3.2 Clinical Development 11.3.2.1 Clinical Trials Information 11.3.3 Safety and Efficacy 11.4 LEUCETTINIB-21: PERHA PHARMACEUTICALS 11.4.1 Product Description 11.4.2 Clinical Development 11.4.2.1 Clinical Trials Information 11.4.3 Other Developmental Activities 11.4.4 Safety and Efficacy 11.5 BUNTANETAP: ANNOVIS BIO 11.5.1 Product Description 11.5.2 Other Developmental Activities 11.5.3 Safety and Efficacy 11.6 APH-1104: APHIOS THERAPEUTICS 11.6.1 Product Description 11.6.2 Other Developmental Activities 12 DOWN'S SYNDROME: MARKET ANALYSIS 12.1 KEY FINDINGS 12.2 MARKET OUTLOOK 12.3 CONJOINT ANALYSIS 12.4 KEY MARKET FORECAST ASSUMPTIONS 12.5 TOTAL MARKET SIZE OF DOWN'S SYNDROME IN THE 7MM 12.6 UNITED STATES MARKET SIZE 12.6.1 Total Market Size of Down's Syndrome in the United States 12.6.2 Market Size of Down's Syndrome by Therapies in the United States 12.7 EU4 AND THE UK MARKET SIZE 12.7.1 Total Market Size of Down's Syndrome in EU4 and the UK 12.7.2 Market Size of Down's Syndrome by Therapies in EU4 and the UK 12.8 JAPAN MARKET SIZE 12.8.1 Total Market Size of Down's Syndrome in Japan 12.8.2 Market Size of Down's Syndrome by Therapies in Japan 13 UNMET NEEDS 14 SWOT ANALYSIS 15 MARKET ACCESS AND REIMBURSEMENT 15.1 UNITED STATES 15.1.1 Centre for Medicare & Medicaid Services (CMS) 15.2 EU4 AND THE UK 15.2.1 Germany 15.2.2 France 15.2.3 Italy 15.2.4 Spain 15.2.5 United Kingdom 15.3 JAPAN 15.3.1 MHLW 16 APPENDIX 16.1 BIBLIOGRAPHY 16.2 REPORT METHODOLOGY 17 DELVEINSIGHT CAPABILITIES 18 DISCLAIMER 19 ABOUT DELVEINSIGHT Related Reports Down's Syndrome Epidemiology Forecast Down's Syndrome Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Down's syndrome epidemiology trends. Down's Syndrome Pipeline Down's Syndrome Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Down's syndrome companies, including Alzheon, Inc, Connecta Therapeutics, among others. Alport Syndrome Market Alport Syndrome Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alport syndrome companies, including Eloxx Pharmaceuticals, Chinook Therapeutics (A Novartis company), Bayer, Calliditas Therapeutics, Evotec , among others. Alport Syndrome Pipeline Alport Syndrome Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Alport syndrome companies, including Eloxx Pharmaceuticals, Inc., Chinook Therapeutic/Novartis, River 3 Renal Corp., Travere Therapeutics, Inc., Reata Pharmaceuticals, Inc., among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur info@delveinsight.com +14699457679 www.delveinsight.com Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
The devastating toll Hurricane Helene inflicted on Georgia this fall will be felt for years in hard hit parts of the state. The storm caused an estimated $5.5 billion in damage to the state’s agriculture and forestry sectors, plus billions more in property losses — and claimed at least 33 lives. But death and destruction may not be all Helene left behind: New federal projections show the storm might have helped spread invasive species, too. An analysis released this week by the U.S. Geological Survey shows Hurricane Helene may have allowed as many as 222 nonnative and invasive species to infiltrate farther into parts of Florida, Georgia, the Carolinas and even deep into the Appalachian Mountains. Of those, 90 are considered invasive, meaning their potential introduction to new territory could threaten human health, the environment and the economy. Hurricane Milton, which slammed Florida as a Category 3 storm about two weeks after Helene, may have dispersed unwanted critters of its own. The USGS’ early projections show the storm could have spread roughly 114 species, including 56 invasives. Most of Milton’s spread likely occurred on the Florida Peninsula, but rain from the storm that stretched into southeast Georgia could have allowed unwanted plants and creatures to expand their range there, too. The agency did not analyze the effects of Hurricane Debby, which brought heavy flooding to Georgia and the Carolinas in August, though over a much smaller area. USGS started conducting these surveys after major storms following Hurricane Harvey, which triggered historic flooding in the Houston area in 2017. The researchers rely on a mix of stream and river gauge readings, topographical data and information on the known presence of species to make their projections. Hurricane Helene made landfall in late September in Florida’s Big Bend Region as a Category 4 hurricane with sustained winds of 140 miles per hour, ranking as one of the strongest storms on record to hit the U.S. Helene’s powerful winds mangled structures, crops and timber stocks across Georgia, but the inland flooding it unleashed — especially in the Carolinas and Tennessee — was to blame for the most severe damage. Those same floodwaters may have provided avenues for invasives to spread, particularly aquatic species, said Ian Pfingsten, a USGS botanist who contributed to the analyses for Helene and Milton. An estimated 100 species had the potential to spread in Georgia via flooding or swollen waterways caused by the storms, Pfingsten said. “We’re dealing with species that can not only float and disperse, like plants and mollusks, but also a lot of fish that will actively swim through the floodwaters,” he said. Among the most concerning species that may have capitalized on the temporary travel corridors in Georgia are the Asian swamp eel, the giant applesnail and the cane toad. Asian swamp eels , Monopterus albus, are native to India, Myanmar, China and other pockets of Asia but were introduced into ponds around the Chattahoochee Nature Center in Roswell in the mid-1990s , likely after being dumped from a home aquarium. The species has since proliferated in the Chattahoochee River Basin, particularly around Atlanta. Atlanta saw record rainfall and major flooding during Helene , especially along tributaries of the Chattahoochee, and USGS experts said the high water could have given the eels an opportunity to venture downstream. Asian swamp eels are known to harbor dangerous parasites that can harm humans and other animals. Giant applesnails , Pomacea maculata, might have also benefited from the storms. Native to the Amazon River basin and other parts of South America, the giant snails are already found in many Georgia waterways, including the Upper Chattahoochee River, the Lower Flint River and many more across South Georgia. The snails are typically tan-brown or yellow and black with striped patterns, but are best distinguished by the wide opening to their shell. Applesnails are a known agricultural pest and, like eels, carry dangerous nematodes capable of causing serious illness in humans. Then there’s the cane toad , Rhinella marina, an enormous, wart-covered amphibian native to South America. The toads, which can weigh as much as 3 pounds, are already established in Florida and pockets of the Gulf Coast. Cane toads pack glands containing a toxic secretion that can poison dogs, cats and even people who come into contact with it. Georgia wildlife officials say there have been sporadic cane toad sightings in the state before, but no breeding populations have been confirmed. USGS experts said there are no indications for now the hurricanes brought more of the pests to Georgia, but it could have been possible for tadpoles to hitch a ride in floodwaters. Georgia already has its share of destructive invasive species. Just weeks ago, state agriculture officials confirmed the spotted lanternfly, an invasive fly known for its stinky and destructive secretions, has been found in the state , but its arrival is likely unrelated to the hurricanes. Still, Georgia officials said they are keeping their eyes open — and have asked the public to do the same. A spokesperson for the Georgia Department of Agriculture said the agency has not seen an uptick in invasives after past storms but encouraged Georgians to remain vigilant if they see unusual plants, insects or animals. The public can report potential sightings, adding that it is “vital” that photos or specimens themselves are captured, if it’s safe to do so. The Georgia Department of Natural Resources said it is aware that storms can help spread invasive species, but so far, staff contacted had not confirmed any new cases linked to hurricane season. ©2024 The Atlanta Journal-Constitution. Visit at ajc.com . Distributed by Tribune Content Agency, LLC.